nodes	percent_of_prediction	percent_of_DWPC	metapath
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—LPAR1—hematologic cancer	0.00105	0.0146	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL17—hematologic cancer	0.000996	0.0139	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR5—hematologic cancer	0.000978	0.0136	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCR7—hematologic cancer	0.000864	0.012	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL13—hematologic cancer	0.000864	0.012	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—TRH—hematologic cancer	0.000803	0.0112	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—LPAR1—hematologic cancer	0.000778	0.0108	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CCL17—hematologic cancer	0.000759	0.0106	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCR5—hematologic cancer	0.000745	0.0104	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—RASGRP1—hematologic cancer	0.000737	0.0103	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CNR2—hematologic cancer	0.000716	0.00997	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—hematologic cancer	0.000659	0.00919	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCL13—hematologic cancer	0.000658	0.00917	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CCR7—hematologic cancer	0.000658	0.00917	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL3—hematologic cancer	0.000615	0.00858	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—TRH—hematologic cancer	0.000611	0.00852	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GRB2—hematologic cancer	0.000593	0.00826	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—PTGER4—hematologic cancer	0.000592	0.00826	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—LPAR1—hematologic cancer	0.000592	0.00825	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CNR2—hematologic cancer	0.000545	0.0076	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR4—hematologic cancer	0.000523	0.00729	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—JAK1—hematologic cancer	0.000511	0.00712	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RHOJ—hematologic cancer	0.000501	0.00698	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—ARHGEF12—hematologic cancer	0.00049	0.00684	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—ARHGEF1—hematologic cancer	0.000478	0.00666	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CCL3—hematologic cancer	0.000469	0.00653	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—PTHLH—hematologic cancer	0.000463	0.00646	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—PTGER4—hematologic cancer	0.000451	0.00629	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IFT172—hematologic cancer	0.000446	0.00622	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—ARHGEF12—hematologic cancer	0.000445	0.00621	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—ARHGEF1—hematologic cancer	0.000434	0.00605	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCR5—hematologic cancer	0.000421	0.00586	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PPEF1—hematologic cancer	0.000408	0.00569	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—GNA13—hematologic cancer	0.000406	0.00566	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—TIAM1—hematologic cancer	0.0004	0.00557	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCR4—hematologic cancer	0.000398	0.00555	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—hematologic cancer	0.000391	0.00545	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CCL17—hematologic cancer	0.000389	0.00543	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—JAK3—hematologic cancer	0.000388	0.0054	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCR5—hematologic cancer	0.000382	0.00533	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CREB1—hematologic cancer	0.000379	0.00528	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL13—hematologic cancer	0.000372	0.00518	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CCR7—hematologic cancer	0.000372	0.00518	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—hematologic cancer	0.000369	0.00515	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—PIK3R1—hematologic cancer	0.000369	0.00514	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GNA13—hematologic cancer	0.000369	0.00514	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—TIAM1—hematologic cancer	0.000363	0.00506	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—IL3RA—hematologic cancer	0.000362	0.00505	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—JAK3—hematologic cancer	0.000352	0.00491	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—hematologic cancer	0.000352	0.0049	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—RGS2—hematologic cancer	0.000349	0.00487	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—TRH—hematologic cancer	0.000346	0.00482	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—TRIO—hematologic cancer	0.000346	0.00482	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCL13—hematologic cancer	0.000338	0.0047	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CCR7—hematologic cancer	0.000338	0.0047	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—LPAR1—hematologic cancer	0.000335	0.00466	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3R1—hematologic cancer	0.00033	0.0046	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL3RA—hematologic cancer	0.000329	0.00458	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HDAC11—hematologic cancer	0.000323	0.0045	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—hematologic cancer	0.000321	0.00447	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—RGS2—hematologic cancer	0.000317	0.00442	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—TRH—hematologic cancer	0.000314	0.00437	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—TRIO—hematologic cancer	0.000314	0.00437	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—BCR—hematologic cancer	0.000309	0.00431	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PDE4B—hematologic cancer	0.000308	0.00429	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CNR2—hematologic cancer	0.000308	0.00429	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—LPAR1—hematologic cancer	0.000304	0.00424	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—RAC2—hematologic cancer	0.000303	0.00422	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—ADCY7—hematologic cancer	0.00029	0.00404	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HDAC10—hematologic cancer	0.000288	0.00401	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PDE4B—hematologic cancer	0.00028	0.0039	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CNR2—hematologic cancer	0.00028	0.0039	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—RAC2—hematologic cancer	0.000275	0.00383	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL2—hematologic cancer	0.000274	0.00382	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ARHGEF12—hematologic cancer	0.000263	0.00367	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—ADCY7—hematologic cancer	0.000263	0.00366	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PTHLH—hematologic cancer	0.000262	0.00365	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ARHGEF1—hematologic cancer	0.000256	0.00357	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PTGER4—hematologic cancer	0.000255	0.00355	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CCL3—hematologic cancer	0.00024	0.00335	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PTHLH—hematologic cancer	0.000238	0.00331	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—hematologic cancer	0.000235	0.00327	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PTGER4—hematologic cancer	0.000231	0.00323	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AGRN—hematologic cancer	0.00023	0.0032	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCL17—hematologic cancer	0.00023	0.0032	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCR5—hematologic cancer	0.000226	0.00315	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCR4—hematologic cancer	0.000225	0.00314	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—hematologic cancer	0.000225	0.00314	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—LEF1—hematologic cancer	0.000222	0.00309	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GNA13—hematologic cancer	0.000218	0.00304	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—IL3—hematologic cancer	0.000217	0.00303	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TIAM1—hematologic cancer	0.000214	0.00299	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—RASGRP1—hematologic cancer	0.00021	0.00293	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CCL2—hematologic cancer	0.000209	0.00291	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—JAK3—hematologic cancer	0.000208	0.0029	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—PIK3CA—hematologic cancer	0.000208	0.00289	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCR4—hematologic cancer	0.000204	0.00285	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—hematologic cancer	0.000202	0.00282	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCR7—hematologic cancer	0.000199	0.00278	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCL13—hematologic cancer	0.000199	0.00278	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL3—hematologic cancer	0.000197	0.00275	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NCOR2—hematologic cancer	0.000197	0.00274	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL3RA—hematologic cancer	0.000194	0.00271	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CRKL—hematologic cancer	0.000194	0.00271	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—RASGRP1—hematologic cancer	0.000191	0.00266	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—GRB2—hematologic cancer	0.000189	0.00263	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RGS2—hematologic cancer	0.000187	0.00261	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—hematologic cancer	0.000186	0.00259	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TRH—hematologic cancer	0.000185	0.00258	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CMA1—hematologic cancer	0.000185	0.00258	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TRIO—hematologic cancer	0.000185	0.00258	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AGO2—hematologic cancer	0.000181	0.00253	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SPHK1—hematologic cancer	0.000181	0.00253	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HDAC9—hematologic cancer	0.00018	0.0025	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—LPAR1—hematologic cancer	0.00018	0.0025	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—H3F3B—hematologic cancer	0.000178	0.00248	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—hematologic cancer	0.000172	0.0024	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GRB2—hematologic cancer	0.000172	0.00239	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CSF2—hematologic cancer	0.000169	0.00235	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PDE4B—hematologic cancer	0.000165	0.0023	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CNR2—hematologic cancer	0.000165	0.0023	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—hematologic cancer	0.000164	0.00229	CbGpPWpGaD
Nafarelin—Asthenia—Irinotecan—hematologic cancer	0.000164	0.000177	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FGF19—hematologic cancer	0.000164	0.00228	CbGpPWpGaD
Nafarelin—Myalgia—Betamethasone—hematologic cancer	0.000163	0.000176	CcSEcCtD
Nafarelin—Myalgia—Dexamethasone—hematologic cancer	0.000163	0.000176	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PRKCG—hematologic cancer	0.000163	0.00227	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—JAK1—hematologic cancer	0.000163	0.00227	CbGpPWpGaD
Nafarelin—Vomiting—Thalidomide—hematologic cancer	0.000163	0.000175	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—RAC2—hematologic cancer	0.000163	0.00227	CbGpPWpGaD
Nafarelin—Dizziness—Carmustine—hematologic cancer	0.000163	0.000175	CcSEcCtD
Nafarelin—Constipation—Etoposide—hematologic cancer	0.000163	0.000175	CcSEcCtD
Nafarelin—Conjunctivitis—Epirubicin—hematologic cancer	0.000162	0.000175	CcSEcCtD
Nafarelin—Dysuria—Doxorubicin—hematologic cancer	0.000162	0.000175	CcSEcCtD
Nafarelin—Rash—Thalidomide—hematologic cancer	0.000161	0.000174	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—DKK1—hematologic cancer	0.000161	0.00225	CbGpPWpGaD
Nafarelin—Dermatitis—Thalidomide—hematologic cancer	0.000161	0.000174	CcSEcCtD
Nafarelin—Dizziness—Alitretinoin—hematologic cancer	0.000161	0.000173	CcSEcCtD
Nafarelin—Diarrhoea—Vincristine—hematologic cancer	0.000161	0.000173	CcSEcCtD
Nafarelin—Headache—Thalidomide—hematologic cancer	0.00016	0.000173	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—STAT5B—hematologic cancer	0.00016	0.00223	CbGpPWpGaD
Nafarelin—Asthenia—Gemcitabine—hematologic cancer	0.00016	0.000172	CcSEcCtD
Nafarelin—Dizziness—Ifosfamide—hematologic cancer	0.000159	0.000171	CcSEcCtD
Nafarelin—Weight increased—Doxorubicin—hematologic cancer	0.000158	0.00017	CcSEcCtD
Nafarelin—Epistaxis—Epirubicin—hematologic cancer	0.000158	0.00017	CcSEcCtD
Nafarelin—Pruritus—Gemcitabine—hematologic cancer	0.000157	0.00017	CcSEcCtD
Nafarelin—Nausea—Thiotepa—hematologic cancer	0.000157	0.000169	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	0.000157	0.000169	CcSEcCtD
Nafarelin—Weight decreased—Doxorubicin—hematologic cancer	0.000157	0.000169	CcSEcCtD
Nafarelin—Sinusitis—Epirubicin—hematologic cancer	0.000157	0.000169	CcSEcCtD
Nafarelin—Oedema—Dexamethasone—hematologic cancer	0.000156	0.000168	CcSEcCtD
Nafarelin—Oedema—Betamethasone—hematologic cancer	0.000156	0.000168	CcSEcCtD
Nafarelin—Diarrhoea—Mitoxantrone—hematologic cancer	0.000156	0.000168	CcSEcCtD
Nafarelin—Diarrhoea—Irinotecan—hematologic cancer	0.000156	0.000168	CcSEcCtD
Nafarelin—Vomiting—Carmustine—hematologic cancer	0.000156	0.000168	CcSEcCtD
Nafarelin—Insomnia—Triamcinolone—hematologic cancer	0.000156	0.000168	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—ADCY7—hematologic cancer	0.000155	0.00216	CbGpPWpGaD
Nafarelin—Dizziness—Vincristine—hematologic cancer	0.000155	0.000167	CcSEcCtD
Nafarelin—Rash—Carmustine—hematologic cancer	0.000155	0.000167	CcSEcCtD
Nafarelin—Dermatitis—Carmustine—hematologic cancer	0.000155	0.000167	CcSEcCtD
Nafarelin—Vomiting—Alitretinoin—hematologic cancer	0.000155	0.000167	CcSEcCtD
Nafarelin—Paraesthesia—Triamcinolone—hematologic cancer	0.000155	0.000167	CcSEcCtD
Nafarelin—Headache—Carmustine—hematologic cancer	0.000154	0.000166	CcSEcCtD
Nafarelin—Shock—Dexamethasone—hematologic cancer	0.000154	0.000166	CcSEcCtD
Nafarelin—Shock—Betamethasone—hematologic cancer	0.000154	0.000166	CcSEcCtD
Nafarelin—Dyspnoea—Triamcinolone—hematologic cancer	0.000154	0.000166	CcSEcCtD
Nafarelin—Rash—Alitretinoin—hematologic cancer	0.000154	0.000165	CcSEcCtD
Nafarelin—Dermatitis—Alitretinoin—hematologic cancer	0.000153	0.000165	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CSF2—hematologic cancer	0.000153	0.00214	CbGpPWpGaD
Nafarelin—Vomiting—Ifosfamide—hematologic cancer	0.000153	0.000165	CcSEcCtD
Nafarelin—Headache—Alitretinoin—hematologic cancer	0.000153	0.000164	CcSEcCtD
Nafarelin—Diarrhoea—Gemcitabine—hematologic cancer	0.000152	0.000164	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—IL2RA—hematologic cancer	0.000152	0.00212	CbGpPWpGaD
Nafarelin—Nausea—Thalidomide—hematologic cancer	0.000152	0.000164	CcSEcCtD
Nafarelin—Rash—Ifosfamide—hematologic cancer	0.000152	0.000163	CcSEcCtD
Nafarelin—Dermatitis—Ifosfamide—hematologic cancer	0.000152	0.000163	CcSEcCtD
Nafarelin—Hyperhidrosis—Betamethasone—hematologic cancer	0.000151	0.000163	CcSEcCtD
Nafarelin—Hyperhidrosis—Dexamethasone—hematologic cancer	0.000151	0.000163	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—XIAP—hematologic cancer	0.000151	0.00211	CbGpPWpGaD
Nafarelin—Dizziness—Irinotecan—hematologic cancer	0.000151	0.000163	CcSEcCtD
Nafarelin—Urticaria—Etoposide—hematologic cancer	0.000151	0.000163	CcSEcCtD
Nafarelin—Rhinitis—Epirubicin—hematologic cancer	0.00015	0.000162	CcSEcCtD
Nafarelin—Conjunctivitis—Doxorubicin—hematologic cancer	0.00015	0.000162	CcSEcCtD
Nafarelin—Vertigo—Prednisone—hematologic cancer	0.00015	0.000162	CcSEcCtD
Nafarelin—Vomiting—Vincristine—hematologic cancer	0.000149	0.000161	CcSEcCtD
Nafarelin—Anorexia—Dexamethasone—hematologic cancer	0.000149	0.000161	CcSEcCtD
Nafarelin—Anorexia—Betamethasone—hematologic cancer	0.000149	0.000161	CcSEcCtD
Nafarelin—Urticaria—Prednisolone—hematologic cancer	0.000149	0.00016	CcSEcCtD
Nafarelin—Asthenia—Cisplatin—hematologic cancer	0.000149	0.00016	CcSEcCtD
Nafarelin—Rash—Vincristine—hematologic cancer	0.000148	0.000159	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PRKCG—hematologic cancer	0.000148	0.00206	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—JAK1—hematologic cancer	0.000148	0.00206	CbGpPWpGaD
Nafarelin—Dermatitis—Vincristine—hematologic cancer	0.000148	0.000159	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—SMARCA4—hematologic cancer	0.000147	0.00205	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SH2B3—hematologic cancer	0.000147	0.00205	CbGpPWpGaD
Nafarelin—Headache—Vincristine—hematologic cancer	0.000147	0.000158	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—GZMB—hematologic cancer	0.000146	0.00204	CbGpPWpGaD
Nafarelin—Nausea—Carmustine—hematologic cancer	0.000146	0.000157	CcSEcCtD
Nafarelin—Epistaxis—Doxorubicin—hematologic cancer	0.000146	0.000157	CcSEcCtD
Nafarelin—Vomiting—Mitoxantrone—hematologic cancer	0.000145	0.000156	CcSEcCtD
Nafarelin—Vomiting—Irinotecan—hematologic cancer	0.000145	0.000156	CcSEcCtD
Nafarelin—Sinusitis—Doxorubicin—hematologic cancer	0.000145	0.000156	CcSEcCtD
Nafarelin—Nausea—Alitretinoin—hematologic cancer	0.000145	0.000156	CcSEcCtD
Nafarelin—Convulsion—Prednisone—hematologic cancer	0.000145	0.000156	CcSEcCtD
Nafarelin—Rash—Irinotecan—hematologic cancer	0.000144	0.000155	CcSEcCtD
Nafarelin—Rash—Mitoxantrone—hematologic cancer	0.000144	0.000155	CcSEcCtD
Nafarelin—Dermatitis—Mitoxantrone—hematologic cancer	0.000144	0.000155	CcSEcCtD
Nafarelin—Dermatitis—Irinotecan—hematologic cancer	0.000144	0.000155	CcSEcCtD
Nafarelin—Headache—Mitoxantrone—hematologic cancer	0.000143	0.000154	CcSEcCtD
Nafarelin—Headache—Irinotecan—hematologic cancer	0.000143	0.000154	CcSEcCtD
Nafarelin—Nausea—Ifosfamide—hematologic cancer	0.000143	0.000154	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CTNNA1—hematologic cancer	0.000143	0.00199	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	0.000142	0.000154	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Betamethasone—hematologic cancer	0.000142	0.000154	CcSEcCtD
Nafarelin—Arthralgia—Prednisone—hematologic cancer	0.000142	0.000153	CcSEcCtD
Nafarelin—Myalgia—Prednisone—hematologic cancer	0.000142	0.000153	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—EIF4EBP1—hematologic cancer	0.000142	0.00198	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HSPB1—hematologic cancer	0.000142	0.00198	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCL3—hematologic cancer	0.000142	0.00198	CbGpPWpGaD
Nafarelin—Diarrhoea—Cisplatin—hematologic cancer	0.000142	0.000153	CcSEcCtD
Nafarelin—Alopecia—Methotrexate—hematologic cancer	0.000142	0.000153	CcSEcCtD
Nafarelin—Vomiting—Gemcitabine—hematologic cancer	0.000141	0.000152	CcSEcCtD
Nafarelin—Insomnia—Betamethasone—hematologic cancer	0.000141	0.000152	CcSEcCtD
Nafarelin—Insomnia—Dexamethasone—hematologic cancer	0.000141	0.000152	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PTHLH—hematologic cancer	0.00014	0.00196	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SDC1—hematologic cancer	0.00014	0.00196	CbGpPWpGaD
Nafarelin—Paraesthesia—Betamethasone—hematologic cancer	0.00014	0.000151	CcSEcCtD
Nafarelin—Paraesthesia—Dexamethasone—hematologic cancer	0.00014	0.000151	CcSEcCtD
Nafarelin—Mental disorder—Methotrexate—hematologic cancer	0.00014	0.000151	CcSEcCtD
Nafarelin—Rash—Gemcitabine—hematologic cancer	0.00014	0.000151	CcSEcCtD
Nafarelin—Dermatitis—Gemcitabine—hematologic cancer	0.00014	0.000151	CcSEcCtD
Nafarelin—Malnutrition—Methotrexate—hematologic cancer	0.000139	0.00015	CcSEcCtD
Nafarelin—Headache—Gemcitabine—hematologic cancer	0.000139	0.00015	CcSEcCtD
Nafarelin—Nausea—Vincristine—hematologic cancer	0.000139	0.00015	CcSEcCtD
Nafarelin—Rhinitis—Doxorubicin—hematologic cancer	0.000139	0.00015	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—IL2RA—hematologic cancer	0.000138	0.00193	CbGpPWpGaD
Nafarelin—Urticaria—Triamcinolone—hematologic cancer	0.000137	0.000148	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PTGER4—hematologic cancer	0.000137	0.00191	CbGpPWpGaD
Nafarelin—Dysgeusia—Methotrexate—hematologic cancer	0.000137	0.000147	CcSEcCtD
Nafarelin—Asthenia—Etoposide—hematologic cancer	0.000136	0.000147	CcSEcCtD
Nafarelin—Oedema—Prednisone—hematologic cancer	0.000136	0.000147	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—LCK—hematologic cancer	0.000136	0.0019	CbGpPWpGaD
Nafarelin—Decreased appetite—Dexamethasone—hematologic cancer	0.000136	0.000146	CcSEcCtD
Nafarelin—Decreased appetite—Betamethasone—hematologic cancer	0.000136	0.000146	CcSEcCtD
Nafarelin—Nausea—Mitoxantrone—hematologic cancer	0.000136	0.000146	CcSEcCtD
Nafarelin—Nausea—Irinotecan—hematologic cancer	0.000136	0.000146	CcSEcCtD
Nafarelin—Pruritus—Etoposide—hematologic cancer	0.000134	0.000145	CcSEcCtD
Nafarelin—Shock—Prednisone—hematologic cancer	0.000134	0.000144	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—H3F3A—hematologic cancer	0.000133	0.00186	CbGpPWpGaD
Nafarelin—Alopecia—Epirubicin—hematologic cancer	0.000132	0.000143	CcSEcCtD
Nafarelin—Nausea—Gemcitabine—hematologic cancer	0.000132	0.000142	CcSEcCtD
Nafarelin—Vomiting—Cisplatin—hematologic cancer	0.000132	0.000142	CcSEcCtD
Nafarelin—Hyperhidrosis—Prednisone—hematologic cancer	0.000132	0.000142	CcSEcCtD
Nafarelin—Mental disorder—Epirubicin—hematologic cancer	0.000131	0.000142	CcSEcCtD
Nafarelin—Rash—Cisplatin—hematologic cancer	0.000131	0.000141	CcSEcCtD
Nafarelin—Dermatitis—Cisplatin—hematologic cancer	0.000131	0.000141	CcSEcCtD
Nafarelin—Malnutrition—Epirubicin—hematologic cancer	0.000131	0.000141	CcSEcCtD
Nafarelin—Diarrhoea—Etoposide—hematologic cancer	0.00013	0.00014	CcSEcCtD
Nafarelin—Anorexia—Prednisone—hematologic cancer	0.00013	0.00014	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PRKCZ—hematologic cancer	0.00013	0.00181	CbGpPWpGaD
Nafarelin—Tension—Epirubicin—hematologic cancer	0.000128	0.000138	CcSEcCtD
Nafarelin—Dysgeusia—Epirubicin—hematologic cancer	0.000128	0.000138	CcSEcCtD
Nafarelin—Nervousness—Epirubicin—hematologic cancer	0.000127	0.000137	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CG—hematologic cancer	0.000127	0.00177	CbGpPWpGaD
Nafarelin—Dizziness—Etoposide—hematologic cancer	0.000126	0.000135	CcSEcCtD
Nafarelin—Vertigo—Methotrexate—hematologic cancer	0.000125	0.000135	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PARP1—hematologic cancer	0.000125	0.00175	CbGpPWpGaD
Nafarelin—Urticaria—Betamethasone—hematologic cancer	0.000124	0.000134	CcSEcCtD
Nafarelin—Urticaria—Dexamethasone—hematologic cancer	0.000124	0.000134	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Prednisone—hematologic cancer	0.000124	0.000134	CcSEcCtD
Nafarelin—Dizziness—Prednisolone—hematologic cancer	0.000124	0.000134	CcSEcCtD
Nafarelin—Asthenia—Triamcinolone—hematologic cancer	0.000124	0.000133	CcSEcCtD
Nafarelin—Nausea—Cisplatin—hematologic cancer	0.000123	0.000133	CcSEcCtD
Nafarelin—Insomnia—Prednisone—hematologic cancer	0.000123	0.000133	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FBXW7—hematologic cancer	0.000123	0.00172	CbGpPWpGaD
Nafarelin—Alopecia—Doxorubicin—hematologic cancer	0.000123	0.000132	CcSEcCtD
Nafarelin—Paraesthesia—Prednisone—hematologic cancer	0.000122	0.000132	CcSEcCtD
Nafarelin—Pruritus—Triamcinolone—hematologic cancer	0.000122	0.000131	CcSEcCtD
Nafarelin—Mental disorder—Doxorubicin—hematologic cancer	0.000122	0.000131	CcSEcCtD
Nafarelin—Convulsion—Methotrexate—hematologic cancer	0.000121	0.00013	CcSEcCtD
Nafarelin—Vomiting—Etoposide—hematologic cancer	0.000121	0.00013	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CXCR4—hematologic cancer	0.000121	0.00168	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HDAC2—hematologic cancer	0.000121	0.00168	CbGpPWpGaD
Nafarelin—Malnutrition—Doxorubicin—hematologic cancer	0.000121	0.00013	CcSEcCtD
Nafarelin—Rash—Etoposide—hematologic cancer	0.00012	0.000129	CcSEcCtD
Nafarelin—Dermatitis—Etoposide—hematologic cancer	0.00012	0.000129	CcSEcCtD
Nafarelin—Headache—Etoposide—hematologic cancer	0.000119	0.000128	CcSEcCtD
Nafarelin—Chest pain—Methotrexate—hematologic cancer	0.000119	0.000128	CcSEcCtD
Nafarelin—Arthralgia—Methotrexate—hematologic cancer	0.000119	0.000128	CcSEcCtD
Nafarelin—Myalgia—Methotrexate—hematologic cancer	0.000119	0.000128	CcSEcCtD
Nafarelin—Tension—Doxorubicin—hematologic cancer	0.000119	0.000128	CcSEcCtD
Nafarelin—Decreased appetite—Prednisone—hematologic cancer	0.000118	0.000128	CcSEcCtD
Nafarelin—Dysgeusia—Doxorubicin—hematologic cancer	0.000118	0.000127	CcSEcCtD
Nafarelin—Rash—Prednisolone—hematologic cancer	0.000118	0.000127	CcSEcCtD
Nafarelin—Dermatitis—Prednisolone—hematologic cancer	0.000118	0.000127	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CBL—hematologic cancer	0.000118	0.00164	CbGpPWpGaD
Nafarelin—Headache—Prednisolone—hematologic cancer	0.000117	0.000126	CcSEcCtD
Nafarelin—Nervousness—Doxorubicin—hematologic cancer	0.000117	0.000126	CcSEcCtD
Nafarelin—Vertigo—Epirubicin—hematologic cancer	0.000117	0.000126	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—IL3—hematologic cancer	0.000116	0.00162	CbGpPWpGaD
Nafarelin—Constipation—Prednisone—hematologic cancer	0.000116	0.000125	CcSEcCtD
Nafarelin—Palpitations—Epirubicin—hematologic cancer	0.000115	0.000124	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CG—hematologic cancer	0.000115	0.0016	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PTPN1—hematologic cancer	0.000115	0.0016	CbGpPWpGaD
Nafarelin—Dizziness—Triamcinolone—hematologic cancer	0.000114	0.000123	CcSEcCtD
Nafarelin—Convulsion—Epirubicin—hematologic cancer	0.000113	0.000122	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PTPN11—hematologic cancer	0.000113	0.00158	CbGpPWpGaD
Nafarelin—Nausea—Etoposide—hematologic cancer	0.000113	0.000122	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—RASGRP1—hematologic cancer	0.000113	0.00157	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HSP90AA1—hematologic cancer	0.000112	0.00157	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SYK—hematologic cancer	0.000112	0.00157	CbGpPWpGaD
Nafarelin—Asthenia—Dexamethasone—hematologic cancer	0.000112	0.000121	CcSEcCtD
Nafarelin—Asthenia—Betamethasone—hematologic cancer	0.000112	0.000121	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CD—hematologic cancer	0.000111	0.00155	CbGpPWpGaD
Nafarelin—Nausea—Prednisolone—hematologic cancer	0.000111	0.00012	CcSEcCtD
Nafarelin—Chest pain—Epirubicin—hematologic cancer	0.000111	0.00012	CcSEcCtD
Nafarelin—Arthralgia—Epirubicin—hematologic cancer	0.000111	0.00012	CcSEcCtD
Nafarelin—Myalgia—Epirubicin—hematologic cancer	0.000111	0.00012	CcSEcCtD
Nafarelin—Pruritus—Betamethasone—hematologic cancer	0.000111	0.000119	CcSEcCtD
Nafarelin—Pruritus—Dexamethasone—hematologic cancer	0.000111	0.000119	CcSEcCtD
Nafarelin—Hyperhidrosis—Methotrexate—hematologic cancer	0.00011	0.000119	CcSEcCtD
Nafarelin—Vomiting—Triamcinolone—hematologic cancer	0.00011	0.000118	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CREB1—hematologic cancer	0.00011	0.00153	CbGpPWpGaD
Nafarelin—Rash—Triamcinolone—hematologic cancer	0.000109	0.000117	CcSEcCtD
Nafarelin—Dermatitis—Triamcinolone—hematologic cancer	0.000109	0.000117	CcSEcCtD
Nafarelin—Vertigo—Doxorubicin—hematologic cancer	0.000109	0.000117	CcSEcCtD
Nafarelin—Anorexia—Methotrexate—hematologic cancer	0.000109	0.000117	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—STAT1—hematologic cancer	0.000108	0.00151	CbGpPWpGaD
Nafarelin—Urticaria—Prednisone—hematologic cancer	0.000108	0.000117	CcSEcCtD
Nafarelin—Headache—Triamcinolone—hematologic cancer	0.000108	0.000116	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CCL2—hematologic cancer	0.000107	0.00149	CbGpPWpGaD
Nafarelin—Diarrhoea—Dexamethasone—hematologic cancer	0.000107	0.000115	CcSEcCtD
Nafarelin—Diarrhoea—Betamethasone—hematologic cancer	0.000107	0.000115	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—IL6R—hematologic cancer	0.000107	0.00149	CbGpPWpGaD
Nafarelin—Palpitations—Doxorubicin—hematologic cancer	0.000107	0.000115	CcSEcCtD
Nafarelin—Oedema—Epirubicin—hematologic cancer	0.000107	0.000115	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3R1—hematologic cancer	0.000105	0.00147	CbGpPWpGaD
Nafarelin—Shock—Epirubicin—hematologic cancer	0.000105	0.000113	CcSEcCtD
Nafarelin—Convulsion—Doxorubicin—hematologic cancer	0.000105	0.000113	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Methotrexate—hematologic cancer	0.000104	0.000112	CcSEcCtD
Nafarelin—Dizziness—Betamethasone—hematologic cancer	0.000103	0.000111	CcSEcCtD
Nafarelin—Dizziness—Dexamethasone—hematologic cancer	0.000103	0.000111	CcSEcCtD
Nafarelin—Hyperhidrosis—Epirubicin—hematologic cancer	0.000103	0.000111	CcSEcCtD
Nafarelin—Insomnia—Methotrexate—hematologic cancer	0.000103	0.000111	CcSEcCtD
Nafarelin—Myalgia—Doxorubicin—hematologic cancer	0.000103	0.000111	CcSEcCtD
Nafarelin—Arthralgia—Doxorubicin—hematologic cancer	0.000103	0.000111	CcSEcCtD
Nafarelin—Chest pain—Doxorubicin—hematologic cancer	0.000103	0.000111	CcSEcCtD
Nafarelin—Nausea—Triamcinolone—hematologic cancer	0.000102	0.00011	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—JAK2—hematologic cancer	0.000102	0.00142	CbGpPWpGaD
Nafarelin—Paraesthesia—Methotrexate—hematologic cancer	0.000102	0.00011	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—MAP2K1—hematologic cancer	0.000102	0.00142	CbGpPWpGaD
Nafarelin—Anorexia—Epirubicin—hematologic cancer	0.000102	0.000109	CcSEcCtD
Nafarelin—Dyspnoea—Methotrexate—hematologic cancer	0.000101	0.000109	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—GRB2—hematologic cancer	0.000101	0.00141	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CD—hematologic cancer	0.000101	0.00141	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PDGFA—hematologic cancer	0.000101	0.00141	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KITLG—hematologic cancer	9.96e-05	0.00139	CbGpPWpGaD
Nafarelin—Vomiting—Dexamethasone—hematologic cancer	9.94e-05	0.000107	CcSEcCtD
Nafarelin—Vomiting—Betamethasone—hematologic cancer	9.94e-05	0.000107	CcSEcCtD
Nafarelin—Decreased appetite—Methotrexate—hematologic cancer	9.89e-05	0.000107	CcSEcCtD
Nafarelin—Rash—Betamethasone—hematologic cancer	9.86e-05	0.000106	CcSEcCtD
Nafarelin—Rash—Dexamethasone—hematologic cancer	9.86e-05	0.000106	CcSEcCtD
Nafarelin—Oedema—Doxorubicin—hematologic cancer	9.86e-05	0.000106	CcSEcCtD
Nafarelin—Dermatitis—Betamethasone—hematologic cancer	9.85e-05	0.000106	CcSEcCtD
Nafarelin—Dermatitis—Dexamethasone—hematologic cancer	9.85e-05	0.000106	CcSEcCtD
Nafarelin—Headache—Betamethasone—hematologic cancer	9.8e-05	0.000106	CcSEcCtD
Nafarelin—Headache—Dexamethasone—hematologic cancer	9.8e-05	0.000106	CcSEcCtD
Nafarelin—Asthenia—Prednisone—hematologic cancer	9.77e-05	0.000105	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—STAT5A—hematologic cancer	9.74e-05	0.00136	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CB—hematologic cancer	9.71e-05	0.00135	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Epirubicin—hematologic cancer	9.71e-05	0.000105	CcSEcCtD
Nafarelin—Shock—Doxorubicin—hematologic cancer	9.7e-05	0.000104	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CDKN2B—hematologic cancer	9.65e-05	0.00135	CbGpPWpGaD
Nafarelin—Pruritus—Prednisone—hematologic cancer	9.64e-05	0.000104	CcSEcCtD
Nafarelin—Insomnia—Epirubicin—hematologic cancer	9.63e-05	0.000104	CcSEcCtD
Nafarelin—Paraesthesia—Epirubicin—hematologic cancer	9.57e-05	0.000103	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PIK3R1—hematologic cancer	9.55e-05	0.00133	CbGpPWpGaD
Nafarelin—Hyperhidrosis—Doxorubicin—hematologic cancer	9.53e-05	0.000103	CcSEcCtD
Nafarelin—Dyspnoea—Epirubicin—hematologic cancer	9.5e-05	0.000102	CcSEcCtD
Nafarelin—Anorexia—Doxorubicin—hematologic cancer	9.4e-05	0.000101	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CD86—hematologic cancer	9.34e-05	0.0013	CbGpPWpGaD
Nafarelin—Diarrhoea—Prednisone—hematologic cancer	9.32e-05	0.0001	CcSEcCtD
Nafarelin—Nausea—Betamethasone—hematologic cancer	9.29e-05	0.0001	CcSEcCtD
Nafarelin—Nausea—Dexamethasone—hematologic cancer	9.29e-05	0.0001	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—JAK2—hematologic cancer	9.28e-05	0.00129	CbGpPWpGaD
Nafarelin—Decreased appetite—Epirubicin—hematologic cancer	9.26e-05	9.98e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—HES1—hematologic cancer	9.21e-05	0.00128	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NCOR1—hematologic cancer	9.15e-05	0.00128	CbGpPWpGaD
Nafarelin—Constipation—Epirubicin—hematologic cancer	9.11e-05	9.81e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FGF1—hematologic cancer	9.05e-05	0.00126	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CSF2—hematologic cancer	9.05e-05	0.00126	CbGpPWpGaD
Nafarelin—Urticaria—Methotrexate—hematologic cancer	9.04e-05	9.74e-05	CcSEcCtD
Nafarelin—Dizziness—Prednisone—hematologic cancer	9.01e-05	9.7e-05	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	8.98e-05	9.67e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FOXO1—hematologic cancer	8.92e-05	0.00124	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—IL2—hematologic cancer	8.92e-05	0.00124	CbGpPWpGaD
Nafarelin—Insomnia—Doxorubicin—hematologic cancer	8.91e-05	9.6e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PDGFRB—hematologic cancer	8.91e-05	0.00124	CbGpPWpGaD
Nafarelin—Paraesthesia—Doxorubicin—hematologic cancer	8.85e-05	9.53e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CB—hematologic cancer	8.82e-05	0.00123	CbGpPWpGaD
Nafarelin—Dyspnoea—Doxorubicin—hematologic cancer	8.79e-05	9.47e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PDGFRA—hematologic cancer	8.77e-05	0.00122	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—JAK1—hematologic cancer	8.74e-05	0.00122	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PRKCG—hematologic cancer	8.74e-05	0.00122	CbGpPWpGaD
Nafarelin—Vomiting—Prednisone—hematologic cancer	8.66e-05	9.33e-05	CcSEcCtD
Nafarelin—Rash—Prednisone—hematologic cancer	8.59e-05	9.25e-05	CcSEcCtD
Nafarelin—Dermatitis—Prednisone—hematologic cancer	8.58e-05	9.24e-05	CcSEcCtD
Nafarelin—Decreased appetite—Doxorubicin—hematologic cancer	8.57e-05	9.23e-05	CcSEcCtD
Nafarelin—Headache—Prednisone—hematologic cancer	8.53e-05	9.19e-05	CcSEcCtD
Nafarelin—Urticaria—Epirubicin—hematologic cancer	8.46e-05	9.12e-05	CcSEcCtD
Nafarelin—Constipation—Doxorubicin—hematologic cancer	8.43e-05	9.08e-05	CcSEcCtD
Nafarelin—Asthenia—Methotrexate—hematologic cancer	8.17e-05	8.8e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—IL2RA—hematologic cancer	8.16e-05	0.00114	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL2—hematologic cancer	8.1e-05	0.00113	CbGpPWpGaD
Nafarelin—Nausea—Prednisone—hematologic cancer	8.09e-05	8.72e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—TERT—hematologic cancer	8.07e-05	0.00112	CbGpPWpGaD
Nafarelin—Pruritus—Methotrexate—hematologic cancer	8.05e-05	8.68e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PDGFB—hematologic cancer	7.88e-05	0.0011	CbGpPWpGaD
Nafarelin—Urticaria—Doxorubicin—hematologic cancer	7.83e-05	8.44e-05	CcSEcCtD
Nafarelin—Diarrhoea—Methotrexate—hematologic cancer	7.79e-05	8.39e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—TSC2—hematologic cancer	7.7e-05	0.00107	CbGpPWpGaD
Nafarelin—Asthenia—Epirubicin—hematologic cancer	7.64e-05	8.23e-05	CcSEcCtD
Nafarelin—Pruritus—Epirubicin—hematologic cancer	7.54e-05	8.12e-05	CcSEcCtD
Nafarelin—Dizziness—Methotrexate—hematologic cancer	7.53e-05	8.11e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FGFR3—hematologic cancer	7.4e-05	0.00103	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAPK14—hematologic cancer	7.33e-05	0.00102	CbGpPWpGaD
Nafarelin—Diarrhoea—Epirubicin—hematologic cancer	7.29e-05	7.85e-05	CcSEcCtD
Nafarelin—Vomiting—Methotrexate—hematologic cancer	7.24e-05	7.8e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—ESR1—hematologic cancer	7.19e-05	0.001	CbGpPWpGaD
Nafarelin—Rash—Methotrexate—hematologic cancer	7.18e-05	7.73e-05	CcSEcCtD
Nafarelin—Dermatitis—Methotrexate—hematologic cancer	7.17e-05	7.72e-05	CcSEcCtD
Nafarelin—Headache—Methotrexate—hematologic cancer	7.13e-05	7.68e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FN1—hematologic cancer	7.1e-05	0.00099	CbGpPWpGaD
Nafarelin—Asthenia—Doxorubicin—hematologic cancer	7.07e-05	7.62e-05	CcSEcCtD
Nafarelin—Dizziness—Epirubicin—hematologic cancer	7.04e-05	7.59e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—BAD—hematologic cancer	7.02e-05	0.000978	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NFKBIA—hematologic cancer	7.02e-05	0.000978	CbGpPWpGaD
Nafarelin—Pruritus—Doxorubicin—hematologic cancer	6.97e-05	7.51e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—NOTCH1—hematologic cancer	6.95e-05	0.000969	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CD80—hematologic cancer	6.81e-05	0.000949	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KIT—hematologic cancer	6.8e-05	0.000947	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CG—hematologic cancer	6.8e-05	0.000947	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—NRAS—hematologic cancer	6.8e-05	0.000947	CbGpPWpGaD
Nafarelin—Vomiting—Epirubicin—hematologic cancer	6.77e-05	7.3e-05	CcSEcCtD
Nafarelin—Nausea—Methotrexate—hematologic cancer	6.76e-05	7.28e-05	CcSEcCtD
Nafarelin—Diarrhoea—Doxorubicin—hematologic cancer	6.74e-05	7.27e-05	CcSEcCtD
Nafarelin—Rash—Epirubicin—hematologic cancer	6.72e-05	7.24e-05	CcSEcCtD
Nafarelin—Dermatitis—Epirubicin—hematologic cancer	6.71e-05	7.23e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PTPN11—hematologic cancer	6.68e-05	0.000931	CbGpPWpGaD
Nafarelin—Headache—Epirubicin—hematologic cancer	6.67e-05	7.19e-05	CcSEcCtD
Nafarelin—Dizziness—Doxorubicin—hematologic cancer	6.52e-05	7.02e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—MAPK3—hematologic cancer	6.51e-05	0.000907	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CREB1—hematologic cancer	6.47e-05	0.000902	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—BRAF—hematologic cancer	6.39e-05	0.000891	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCL2—hematologic cancer	6.33e-05	0.000882	CbGpPWpGaD
Nafarelin—Nausea—Epirubicin—hematologic cancer	6.33e-05	6.82e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—IL6R—hematologic cancer	6.31e-05	0.00088	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CREBBP—hematologic cancer	6.3e-05	0.000878	CbGpPWpGaD
Nafarelin—Vomiting—Doxorubicin—hematologic cancer	6.27e-05	6.75e-05	CcSEcCtD
Nafarelin—Rash—Doxorubicin—hematologic cancer	6.21e-05	6.69e-05	CcSEcCtD
Nafarelin—Dermatitis—Doxorubicin—hematologic cancer	6.21e-05	6.69e-05	CcSEcCtD
Nafarelin—Headache—Doxorubicin—hematologic cancer	6.17e-05	6.65e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—MAP2K1—hematologic cancer	6.02e-05	0.000838	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CD—hematologic cancer	5.98e-05	0.000833	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CA—hematologic cancer	5.92e-05	0.000825	CbGpPWpGaD
Nafarelin—Nausea—Doxorubicin—hematologic cancer	5.85e-05	6.31e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—KRAS—hematologic cancer	5.85e-05	0.000815	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FGF2—hematologic cancer	5.72e-05	0.000797	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3R1—hematologic cancer	5.64e-05	0.000786	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—JAK2—hematologic cancer	5.48e-05	0.000764	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CA—hematologic cancer	5.38e-05	0.000749	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MDM2—hematologic cancer	5.35e-05	0.000746	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CB—hematologic cancer	5.21e-05	0.000726	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MTOR—hematologic cancer	5.21e-05	0.000726	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—HRAS—hematologic cancer	4.97e-05	0.000693	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CDKN1B—hematologic cancer	4.89e-05	0.000681	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AKT1—hematologic cancer	4.84e-05	0.000674	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CASP3—hematologic cancer	4.79e-05	0.000668	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL2—hematologic cancer	4.78e-05	0.000667	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL6—hematologic cancer	4.76e-05	0.000663	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCND1—hematologic cancer	4.66e-05	0.00065	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—JUN—hematologic cancer	4.65e-05	0.000649	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CDKN1A—hematologic cancer	4.51e-05	0.000629	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PTEN—hematologic cancer	4.5e-05	0.000627	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAPK8—hematologic cancer	4.4e-05	0.000614	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AKT1—hematologic cancer	4.39e-05	0.000612	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EP300—hematologic cancer	4.29e-05	0.000598	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SRC—hematologic cancer	4.17e-05	0.000582	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—VEGFA—hematologic cancer	4.07e-05	0.000567	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—STAT3—hematologic cancer	4.03e-05	0.000561	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NRAS—hematologic cancer	4.02e-05	0.00056	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAPK3—hematologic cancer	3.85e-05	0.000536	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MYC—hematologic cancer	3.74e-05	0.000521	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TGFB1—hematologic cancer	3.73e-05	0.00052	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KRAS—hematologic cancer	3.46e-05	0.000482	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CA—hematologic cancer	3.18e-05	0.000443	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TP53—hematologic cancer	3.07e-05	0.000428	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HRAS—hematologic cancer	2.94e-05	0.000409	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL6—hematologic cancer	2.81e-05	0.000392	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AKT1—hematologic cancer	2.59e-05	0.000362	CbGpPWpGaD
